August 1, 1983Journal of Clinical Oncology

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate.

View Full Paper

Ask AI

Bookmark

Why the study?

Does weekly doxorubicin improve response rates and symptoms in patients with endocrine-refractory prostatic carcinoma?

Population

25 patients with endocrine-refractory prostatic carcinoma, all with prior hormonal therapy and 84% with…

Design

Case_series

Authors

FTFrank M. TortiUConn Health DAD AstonVelindre NHS Trust BLB L LumUniversity of the Pacific

Discussion

Member takes

Implication

May palliate symptoms in endocrine-refractory prostate cancer; hypothesis-generating and requires randomized confirmation.

Structured PICO

Does weekly doxorubicin improve response rates and symptoms in patients with endocrine-refractory prostatic carcinoma?

Population

25 patients with endocrine-refractory prostatic carcinoma, all with prior hormonal therapy (68% had two or more prior hormonal maneuvers) and 84% with prior therapeutic or palliative irradiation.

Intervention

Doxorubicin 20 mg/m2 given weekly.

Outcome

Overall response rate by National Prostatic Cancer Project criteriacomposite

Weekly doxorubicin provides a high response rate and effective symptom palliation with minimal toxicity in patients with endocrine-refractory prostate cancer.

Cite This Study

Torti et al. (1983) studied this question.

synapsesocial.com/papers/6a701ed4e36a167817e1db2e https://doi.org/10.1200/jco.1983.1.8.477

View Full Paper

Ask AI

Bookmark

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider